Pharma's battered rep gets a modest facelift in the latest industry ratings from Gallup — but it's still looking pretty bad
When the pandemic started up earlier this year, quite a few pharma execs felt it was the perfect opportunity to mend fences with the American people — which had developed a largely contemptuous view of drug makers. Nothing symbolized the industry’s public relations predicament better than the Gallup poll last September, which had pharma bumped to the very bottom of a long list of industries ranked by the public’s opinion.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.